Terns Announces Pricing of Upsized $150.15 Million Public Offering

a week ago

FOSTER CITY, Calif., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) ( Nasdaq: TERN ) , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and ...

Ticker	Sentiment	Impact
TERN	Neutral	30 %